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Abstract
Background: Most patients with ovarian cancer are diagnosed with advanced stage disease (i.e., stage III-IV), which
is associated with a poor prognosis. Differentially expressed genes (DEGs) in stage III serous ovarian carcinoma
compared to normal tissue were screened by a new differential display method, the annealing control primer
(ACP) system. The potential targets for markers that could be used for diagnosis and prognosis, for stage III serous
ovarian cancer, were found by cluster and survival analysis.
Methods: The ACP-based reverse transcriptase polymerase chain reaction (RT PCR) technique was used to identify
DEGs in patients with stage III serous ovarian carcinoma. The DEGs identified by the ACP system were confirmed
by quantitative real-time PCR. Cluster analysis was performed on the basis of the expression profile produced by
quantitative real-time PCR and survival analysis was carried out by the Kaplan-Meier method and Cox proportional
hazards multivariate model; the results of gene expression were compared between chemo-resistant and chemo-
sensitive groups.
Results: A total of 114 DEGs were identified by the ACP-based RT PCR technique among patients with stage III
serous ovarian carcinoma. The DEGs associated with an apoptosis inhibitory process tended to be up-regulated
clones while the DEGs associated with immune response tended to be down-regulated clones. Cluster analysis of
the gene expression profile obtained by quantitative real-time PCR revealed two contrasting groups of DEGs. That
is, a group of genes including: SSBP1, IFI6 DDT, IFI27, C11orf92, NFKBIA, TNXB, NEAT1 and TFG were up-regulated
while another group of genes consisting of: LAMB2, XRCC6, MEF2C, RBM5, FOXP1, NUDCP2, LGALS3, TMEM185A, and
C1S were down-regulated in most patients. Survival analysis revealed that the up-regulated genes such as DDAH2,
RNase K and TCEAL2 might be associated with a poor prognosis. Furthermore, the prognosis of patients with
chemo-resistance was predicted to be very poor when genes such as RNase K, FOXP1, LAMB2 and MRVI1 were up-
regulated.
Conclusion: The DEGs in patients with stage III serous ovarian cancer were successfully and reliably identified by
the ACP-based RT PCR technique. The DEGs identified in this study might help predict the prognosis of patients
with stage III serous ovarian cancer as well as suggest targets for the development of new treatment regimens.
Background
Ovarian cancer is a complex disease, characterized by
successive accumulation of multiple molecular altera-
tions in both the cells undergoing neoplastic transfor-
mation and host cells [1]. These anomalies disturb the
expression of genes that control critical cell processes,
leading to the initiation of tumorigenesis and develop-
ment. At the time of diagnosis most patients with ovar-
ian cancer have advanced stage disease (i.e., stage III-IV)
where surgery and chemotherapy results in an approxi-
mately 25% overall 5-year survival rate. Consequently,
ovarian cancer is the leading cause of death from a
gynecological malignancy. Epithelial ovarian cancer
(EOC) accounts for 90% of all ovarian cancers; there is
significant heterogeneity within the EOC group. For
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any medium, provided the original work is properly cited.example, histologically defined subtypes such as serous,
endometrioid, mucinous, and low- and high-grade
malignancies all have variable clinical manifestations
and underlying molecular signatures [2].
Gene expression has been extensively applied to
screening for the prognostic factors associated with
ovarian cancer; identification of such factors would help
to determine patient prognosis. Studies have focused on
differential gene expression between tumor and normal
tissues [3], distinguishing between histological subtypes
[4] and identifying differences between invasive tumors
and those with low malignant potential [5]. However, to
date, the use of differentially expressed genes (DEG)
have not been implemented in ovarian cancer therapies;
this is mainly because their reliability and validity have
not yet been well established. Microarray technology
permits large scale analysis of expression surveys to
identify the genes that have altered expression as a
result of disease. However, microarray data is notorious
for its unreliable reproducibility of DEGs across plat-
forms and laboratories, as well as validation problems
associated with prognostic signatures [6]. In addition,
identification of a gene responsible for a specialized
function during a certain biological stage can be difficult
to determine because the gene might be expressed at
low levels, whereas the bulk of mRNA transcripts within
a cell are abundant [7].
To screen DEGs in low concentrations, while minimiz-
ing false positive results, the polymerase chain reaction
(PCR) based technique has been used. One screening
method, differential display, requires PCR using short
arbitrary primers. This method is simple, rapid and only
requires small amounts of total RNA. However, many
investigators have reported significantly high false-posi-
tive rates [8] and poor reproducibility of the results [9]
because of nonspecific annealing by the short arbitrary
primers. Recently, the annealing control primer (ACP)
system has been developed; this technique provides a pri-
mer with annealing specificity to the template and allows
only genuine products to be amplified [10]. The structure
of the ACP includes (i) a 3′ end region with a target core
nucleotide sequence that substantially complements the
template nucleic acid of hybridization; (ii) a 5′ end region
with a non-target universal nucleotide sequence; and (iii)
a polydeoxyinosine [poly(dI)] linker bridging the 3′ and 5′
end sequences. Because of the high annealing specificity
during PCR using the ACP system, the application of the
ACP to DEG identification generates reproducible, accu-
rate, and long (100 bp to 2 kb) PCR products that are
detectable on agarose gels.
In this study, the ACP-based PCR method was used to
identify the DEGs of patients with stage III serous ovar-
ian cancer, the findings were compared to normal ovar-
ian tissue. A total of 60 arbitrary ACPs were used and
114 DEGs were identified by sequencing differentially
expressed bands. For the confirmation of differential
expression of the DEGs, quantitative real-time PCR was
performed on 38 selected DEGs; the results showed good
agreement with the ACP findings. These results could be
used as preliminary data for further study of the molecu-
lar mechanism underlying stage III serous ovarian cancer.
Methods
Patient information
After obtaining written informed consent from all
patients included in the study, samples of primary epithe-
lial ovarian cancer were snap frozen in liquid nitrogen
and stored at -80°C. Analysis of tissues from patients was
approved by the Institutional Review Board of The
Catholic University of Korea (Seoul, Korea). The histo-
pathological diagnoses were determined using the WHO
criteria, and the tumor histotype was serous adenocarci-
noma in all patients. Classification of cancer stage and
grade was performed according to the International Fed-
eration of Gynecology and Obstetrics (FIGO). A total of
16 patients with serous ovarian carcinoma were enrolled
in this study, all patients were diagnosed as stage IIIC
with high-grade cancer (grade 3).
ACP-based GeneFishing™ reverse transcription
polymerase chain reaction
Total RNAs from the ovarian tissues of the serous carci-
noma were isolated by gentle homogenization using Tri-
zol®. The normal human ovary total RNA was purchased
from Stratagene (Total RNA Human Ovary, #540071).
The RNA was used for the synthesis of first-strand cDNAs
by reverse transcriptase. Reverse transcription was per-
formed 1.5 hours at 42°C in a final reaction volume of 20
μl containing 3 μg of the purified total RNA, 4 μlo f5 ′
reaction buffer (Promega, Madison, WI, USA), 5 μlo f
dNTPs (2 mmol each), 2 μlo f1 0μMd T - A C P 1( 5 ′-
CTGTGAATGCTGCGACTACGATIIIII(T)18)-3′,w h e r e
“I” represents deoxyinosine), 0.5 μLo fR N a s i n ®R N a s e
Inhibitor (40 U/μl, Promega), and 1 μl of Moloney murine
leukemia virus reverse transcriptase (200 U/μl, Promega).
First-strand cDNAs were diluted by the addition of 80 μL
of RNase-free water for the GeneFishing PCR and stored
-20°C until use.
DEGs were screened by ACP-based PCR method using
the GeneFishing™ DEG kits (Seegene, Seoul, South
Korea). Briefly, second-strand cDNA synthesis was con-
ducted at 50°C (low stringency) during one cycle of first-
stage PCR in a final reaction volume of 49.5 μl containing
3-5 μl (about 50 ng) of diluted first-strand DNA cDNA,
5 μl of 10x PCR buffer plus Mg (Roche Applied Science,
Mannheim, Germany), 5 μl of dNTP (each 2 mM), 1 μl
of 10 μM dT-ACP2 (5’-CTGTGAATGCTGCGACTAC-
GATIIIII(T)15-3′), and 1 μlo f1 0μM arbitrary ACP. The
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while 0.5 μl of Taq DNA polymerase was added to the
reaction mixture (5 U/μl, Roche Applied Science). Sixty
PCR reactions for each sample were carried out with 60
arbitrary ACPs, respectively. The PCR protocol for sec-
ond-strand synthesis was one cycle at 94°C for 1 min, fol-
lowed by 50°C for 3 min, and 72°C for 1 min. After
completion of second-strand DNA synthesis, 40 cycles
were performed. Each cycle involved denaturation at
94°C for 40 sec, annealing at 65°C for 40 sec, extension at
72°C for 40 sec, and a final extension at 72°C to complete
the reaction. The amplified PCR products were separated
in 2% agarose gel and stained with ethidium bromide.
The overall scheme of the experiment is shown in
Figure 1.
Cloning and sequencing
The differentially expressed bands were extracted from
the gel using the GENCLEAN® II Kit (Q-BIO gene, Carls-
bad, CA.,USA), and directly cloned into a TOPO TA®
cloning vector (Invitrogen, Karlsruhe, Germany) accord-
ing to the manufacturer’s instructions. The cloned
plasmids were sequenced with an ABI PRISM® 3100
Genetic Analyzer (Applied Biosystems, Foster City, CA.,
USA). Complete sequences were analyzed by searching
for similarities using the Basic Local Alignment Search
Tool (BLAST) search program at the Genbank database
of the National Center for Biotechnology Information
(NCBI).
Quantitative real-time polymerase chain reaction and
statistical analysis
For the confirmation of the differential expression of
DEGs, quantitative real-time PCR was carried out for 38
DEGs selected from 114 DEGs. The concentrations of
the reagents were adjusted to reach a final volume of 20
μL containing 5 ng of cDNA template, 10 μlo fS Y B R ®
Premis Ex Taq™ II (Takara Bio,Otsu, Japan), 0.4 μlo f
ROX™ reference Dye II, 0.4 μlo f1 0μMf o r w a r da n d
reverse primers of DEGs with b-actin as an internal con-
trol (Table 1). The cDNA templates were constructed
with the total RNA extracted from 16 ovarian cancer tis-
sues and normal human ovary total RNA. The PCR
amplification protocol was 50°C for 2 min and 95°C for
sample 1 sample2 sample 3 sample 16 ··· sample 1 sample2 sample 3 sample 16 ···
p p
60 arbitrary primers 60 arbitrary primers
Tissue  samples from 16 serous 
ovarian carcinoma patients
Total RNA isolation for each sam le
First-strand cDNA synthesis with dT-ACP1 for each sample  
ACP-based Gene Fishing PCR: 
cDNA synthesis primer (dT-ACP1), 
reverse primer (dT-ACP2), 
Second  strand cDNA synthesis  and subsequent PCR amplification 
with dT-ACP2 and a arbitrary primer for each sample
Gel electrophoresis and extraction of differentially expressed bands 
compared with PCR product band generated from normal sample
DNA purification  from extracted band and cloning of it 
into PGEM®-T vector 
Sequencing of cloned plasmids and similarity search using
BLAST search  program at NCBI Genbank
Confirmation of differential expression of selected genes (clones)  
by quantitative real-time PCR 
Figure 1 A schematic diagram of the experimental procedure.
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30 sec, and 72°C for 30 sec. The real-time PCR analysis
was performed on an Applied Biosystems Prism 7900
Sequence Detection System (Applied Biosystems). Rela-
tive quantification with the data obtained was performed
according to the user’s manual. The fold change for gene
expression, between the cancer and normal samples, was
calculated by using the threshold cycle (CT): fold change
=2
-ΔΔC
T, ΔΔCT =[ ( C T of gene of interest - CT of
b-actin)cancer sample-( C T gene of interest - CT of b-actin)
normal sample) ] .T h ef o l dc h a n g ew a sl o g 2 transformed for
the cluster and survival analysis. The R packages mclust
and survival http://www.r-project.org were used for the
cluster and survival analysis, respectively.
Results
Differentially expressed genes (DEGs) in stage III serous
ovarian cancers
The patients included in this study ranged in age between
38 and 69 (mean age 53.3 ± 7.5 years). All 16 patients had
a diagnosis of FIGO stage III papillary serous ovarian car-
cinoma. To identify genes that showed a predominant
Table 1 Primer sequences of 38 DEGs and b-actin used for the quantitative real-time PCR
DEG Forward Reverse Amplicon size
NM_003143.1 AAAGATCCCTGAATCGTGTGC TCGCCACATCTCATTAGTTGC 119
AY871274 GTCCACTGCACAGTTCGAGG GGCCTCCTCTTTGCTGATTC 279
NM_022873.2 CAGAAGGCGGTATCGCTTTTC CCTGCATCCTTACCCGCATT 89
NM_001355.3 AGCGCCCACTTCTTTGAGTTT TCCCTATCTTGCCAATCTGCC 106
BC000523 GTGCCTAAGACAGAAATTCGGG TGCAAGTCTATGTTTGGGTTCAT 174
NM_005532 GCAGCCTTGTGGCTACTCTG TAGAACCTCGCAATGACAGCC 112
NM_207429.2 GGAGCTCCTTGGAAGTCAGG GCCAGCAACAGCACTGAGAT 129
BC012823 CGCTCTCTTTTCTCCCGTTT TCGCAGCATGCTCAACATTA 236
NM_020529 CTCCGAGACTTTCGAGGAAATAC GCCATTGTAGTTGGTAGCCTTCA 135
NM_001101654 GTGCAATCGCCATTACTGCT GAATGCAGGGTGTAAGGGGT 248
NM_001867 AAAGGTCTTGGTGAGGTGCC ACGGACCACAGAGGTTGTGA 119
BC013003 TCAGCACCTTGGAACCTTTGA AAGACACTCTCTCGGTAGTCATT 100
NM_000978 TCCTCTGGTGCGAAATTCCG CGTCCCTTGATCCCCTTCAC 119
NM_032470 TTGTCCAGATAGCGGCAAAC AGCGAGCTCTGGAAGAGGAG 149
NM_013974.1 GGTCGATGGAGTCCGCAAAG GGTGAAGAGAACGTCAGTGC 100
XM_002345433 CGAGTTCGTGGACCTGTACG GCCATTAAACCTGCCTGTGA 127
NM_001034996 CATGCCGGAAAATTGGTCGC CACTGTGCGGAAACTTGAGGA 145
NM_001037637 CATCTCTGGCAGCGAACACTT AGTCAGACTATCCGCACCAAG 107
BC107854 AGGGGTAAGCTCATCGCAGT CCGGAAAGTGTCTTCGATCTCA 150
NM_001020 TCGGACGCAAGAAGACAGC AGCAGCTTGTACTGTAGCGTG 118
NR_003225 GAAACCCAAACCCTCAAGGA GCACTTGGCTGTCCAGAAGA 247
NM_001004333.3 ATTCCTTGCGCTTATTGAGCC GCCCCCAGAACATATACAACCT 123
NM_080390 TGCAGGGAGGATCAAAGACA GGCTCTCCCTCACTCTCTGG 103
NM_013318 AAGCCCTCTGGATCAGCAGT TCAGTAGGGAGAGGCGAGGT 227
EF177379 GTTTCCAGGCCTTGCTCA ATTCATGGGCTCTGGAACAA 158
AK026649 GGTTCTCGCTCTTGTCGTGTC ATATCCTTCGCGTACTGACGG 101
AK302766 TGGCTTTGTAACAAGTGCTGC CGGAGCTATGTTCCGAAGAATG 168
NM_032682 TCCCGTGTCAGTGGCTATGAT CTCTTTAGGCTGTTTTCCAGCAT 226
NG_001229 TCATGAGGCCCAGATCAAGA ACCACGTCCTTCCCTTTCAG 219
AK025219 AGGACCAGAACTGCAAGCTG GCGCTCTTCCAAGTCAGTGA 155
BC001120 GCAGACAATTTTTCGCTCCA GCACTTGGCTGTCCAGAAGA 287
NM_032508.1 ATGAACCTGAGGGGCCTCTT TGATGCCATCCAAACGAAGGG 106
NM_002292.3 ATGCTGGTGGAACGCTCAG CTCGCCTTCAGTGGATGGC 171
AK293439 GGTCCAGAAGGCTCTCAAGC GGGCCTCAGGTAATGGTGTT 265
NM_001131005 AGACATCGTGGAGGCATTGA GTGGCAATAGGTTGGGGTTT 263
NM_201442 CAAGTCCCATACAACAAACTCCA CAGGAGCAGAAGTAACCACCA 176
BC023599 TCCCTTGTCCGGAGGATATT TAATGGATTCAATCATCTTTATTAACC 164
NM_001100167 TCTGAAGAGTCCCCCAAATG AATCCAGCACTTCCTCTCCA 209
b-actin GGCTGTATTCCCCTCCATCG CCAGTTGGTAACAATGCCATGT 154
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ovarian cancer, the total RNAs from 16 serous ovarian
tissues of stage III and the normal human ovary total
RNA (Stratagene, #540071) were individually subjected
to ACP-based RT PCR analysis using a combination of
60 arbitrary primers and two anchored oligo (dT) pri-
mers (dT-ACP1 and dT-ACP2). All PCR amplicons were
compared on agarose gels (Figure 2). When the bands
generated by the normal sample showed a clear differ-
ence compared to the bands generated on the cancer
sample, the band was defined as a differentially expressed
band. After all poor appearing bands were excluded, the
differentially expressed bands were extracted, amplified
using the TOPO TA Cloning Kit (Invitrogen, Cat.
#K4500-1) and sequenced. The sequences of 114 DEGs
were obtained. The DNA sequence of each DEG was ana-
lyzed by searching for similarities using the BLASTX pro-
gram at the Genbank database (NIH, MD, USA). Table 2
shows the 114 DEGs assessedb yG e n b a n ka n dt h eb e s t
homologues.
The DEGs identified from the clones that were up-
regulated included: AP000659 (U4, ARHGEF12),
NM_013974.1 (U8, DDAH2), NM_022873.2 (U16, IFI6),
NM_020529 (U21, NFKBIA), BC023599 (U30, TFG), and
NG_011683 (U39, SEPT9). The up-regulation of SEPT9
mRNA was reported in a bank of ovarian tumors, which
included benign, borderline and malignant tumors [11].
The genes including DDAH2, IFI6 and NFKBIA are
known to be involved in the apoptosis inhibitory process
while ARHGEF12 and TGF have been implicated in signal-
ing pathways. The DEGs identified from down-regulated
clones included: AK291099 (D7, BST2), NM_001025159.1
(D10, CD74), BC004186 (D18, GNB1), NG_011554 (D34,
HTRA1), BC095490 (D36, IGKC), and BC001693 (D41,
LGALS1). The down-regulation of HTRA1 was associated
with ovarian cancer metastasis [12]. The genes including
BST2, CD74 and IGKC were associated with the immune
system; while GNB1 and LGALS1 were related to the
modulation of cell-cell interaction and the G protein
coupled receptor protein signaling pathway, respectively.
Confirmation of ACP observation by quantitative real-
time PCR and cluster analysis
To confirm the efficacy of the ACP system, confirmation
of the differential expression of DEGs was performed
with quantitative real-time PCR for 38 DEGs selected
from the total 114 DEGs using a specific primer pair for
each gene (Table 1 and Additional file 1). The expres-
sion ratio of the cancer to normal sample was calculated
by using CT and then was log2 transformed (see Meth-
ods section for detail). The DEGs were considered dif-
ferentially expressed if the log2 ratio was > 1.0 or < -1.0.
Differential expression was clearly observed in all 38
DEGs, which indicates a high reliability of the ACP sys-
tem (Figure 3).
For the detection of more conserved expression patterns
in patients with stage III serous ovarian cancer, cluster
analysis was performed using the R package mclust http://
www.r-project.org. Thirty eight DEGs were divided into
four groups according to their expression profiles with
assignment of each gene to a group (Figure 3). A clear
contrast in expression patterns was noted between groups
1 and 4. That is, the overall up- and down-regulation in
group 1 was 86.8% and 5.6%, respectively; the overall up-
and down-regulation in group 4 was 9.3% and 60.3%,
respectively, when up-regulation corresponds to log2 ratio
> 1 and down-regulation to log2 ratio < -1 (Table 3). This
regulation pattern in each group was well maintained at
various thresholds used for definition of differential
expression. These findings suggest that the genes in
Figure 2 An example of GeneFishing™ using an arbitrary ACP in combination with an oligo (dT) ACP as indicated in the Methods
section. M and N represents a 100-bp size marker generated by Forever 100-bp Ladder Personalizer (Seegene, Seoul, South Korea) and a normal
sample, respectively. The lanes 1-16 include each of the cancer samples from the 16 patients. The bands showing a clear difference between the
normal and cancer samples, here marked with a red arrow, were excised from the gel for further cloning and sequencing.
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Clone name Annotation GenBank accession no. E-value
U1 Homo sapiens acidic (leucine-rich) nuclear phosphoprotein 32 family, member B BC013003 4.00E-112
U2 Homo sapiens adaptor-related protein complex 3, delta 1 subunit (AP3D1),
transcript variant 2
NM_003938 6.00E-10
U3 Homo sapiens adenine phosphoribosyltransferase (APRT), transcript variant 2 NM_001030018 7.00E-08
U4 Homo sapiens genomic DNA, chromosome 11q, clone:CMB9-1B14, complete sequences AP000659 4.00E-73
U5 Homo sapiens chromosome 19 open reading frame 53 (C19orf53) NM_014047 1.00E-19
U6 Homo sapiens chromosome 1 open reading frame 115 (C1orf115) NM_024709 5.00E-24
U7 Homo sapiens coatomer protein complex, subunit alpha (COPA), transcript variant 1 NM_001098398 4.00E-22
U8 Homo sapiens dimethylarginine dimethylaminohydrolase 2 (DDAH2) NM_013974.1 2.00E-123
U9 Homo sapiens dimethylarginine dimethylaminohydrolase 2 BC001435 9.00E-168
U10 Homo sapiens dynein, light chain, LC8-type 1 (DYNLL1), transcript variant 3 NM_003746 0.00E+00
U11 Homo sapiens ferritin, light polypeptide BC004245 0.00E+00
U12 Homo sapiens glutamic-oxaloacetic transaminase 2, mitochondrial (aspartate
aminotransferase 2) (GOT2), nuclear gene encoding mitochondrial protein
NM_002080 7.00E-21
U13 Homo sapiens sarcoma antigen NY-SAR-48 BC040564 3.00E-95
U14 Homo sapiens heat shock protein 90 kDa alpha (cytosolic), class B member 1 (HSP90AB1) NM_007355.2 0.00E+00
U15 Homo sapiens interferon, alpha-inducible protein 27 (IFI27), transcript variant 2 NM_005532 6.00E-99
U16 Homo sapiens interferon, alpha-inducible protein 6 (IFI6), transcript variant 3 NM_022873.2 2.00E-35
U17 Homo sapiens iron-responsive element binding protein 2 (IREB2) NM_004136 5.00E-66
U18 Homo sapiens keratinocyte associated protein 2 BC029806 5.00E-71
U19 PREDICTED: Homo sapiens similar to ribosomal protein S21, transcript variant 2
(LOC100291837)
XM_002345433 1.00E-100
U20 Homo sapiens mesothelin (MSLN), transcript variant 1 NM_005823 0.00E+00
U21 Homo sapiens nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor,
alpha (NFKBIA)
NM_020529 1.00E-95
U22 Homo sapiens nuclear distribution gene C homolog (A. nidulans) pseudogene 2 (NUDCP2)
on chromosome 2
NG_001229 1.00E-101
U23 Homo sapiens PRP8 pre-mRNA processing factor 8 homolog (S. cerevisiae) (PRPF8) NM_006445.3 4.00E-110
U24 Homo sapiens RAB5B, member RAS oncogene family (RAB5B) NM_002868 2.00E-123
U25 Homo sapiens cDNA FLJ76524 complete cds AK289930 2.00E-79
U26 Homo sapiens cell growth-inhibiting protein 34 mRNA, complete cds AY871274 0.00E+00
U27 Homo sapiens ribosomal protein L23 (RPL23) NM_000978 1.00E-87
U28 Homo sapiens ribosomal protein L6 pseudogene 27 (RPL6P27) on chromosome 18 NG_009652 2.00E-111
U29 Homo sapiens ribosomal protein S8 (RPS8) NM_001012 2.00E-67
U30 Homo sapiens TRK-fused gene BC023599 4.00E-79
U31 Homo sapiens ribosomal protein S8 BC070875 1.00E-60
U32 Homo sapiens mRNA similar to eukaryotic translation initiation factor 3, subunit 7
(zeta, 66/67 kD)
BC011740 8.00E-142
U33 Homo sapiens ribosomal protein S24 BC000523 4.00E-45
U34 Homo sapiens cDNA, FLJ18539 AK311497 4.00E-26
U35 Homo sapiens cDNA clone IMAGE:2822193 BC005845 8.00E-155
U36 Homo sapiens ATPase, H+ transporting, lysosomal 14 kDa, V1 subunit F BC107854 3.00E-147
U37 Homo sapiens cytochrome c oxidase subunit VIIc (COX7C), nuclear gene encoding
mitochondrial protein
NM_001867 5.00E-145
U38 Homo sapiens tenascin XB (TNXB), transcript variant XB-S NM_032470 0.00E+00
U39 Homo sapiens septin 9 (SEPT9) on chromosome 17 NG_011683 5.00E-45
U40 Homo sapiens chromosome 11 open reading frame 92 (C11orf92) NM_207429.2 3.00E-45
U41 Homo sapiens D-dopachrome tautomerase (DDT), transcript variant 1 NM_001355.3 5.00E-94
U42 Homo sapiens single-stranded DNA binding protein 1 (SSBP1) NM_003143.1 0.00E+00
D1 Homo sapiens actin, beta (ACTB), NM_001101.2 0.00E+00
D2 Homo sapiens acidic (leucine-rich) nuclear phosphoprotein 32 family, member B (ANP32B) NM_006401.2 4.00E-115
D3 Homo sapiens Rho guanine nucleotide exchange factor (GEF) 17 (ARHGEF17) NM_014786 7.00E-37
D4 Homo sapiens ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G1 BC003564 0.00E+00
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D5 Homo sapiens UDP-Gal:betaGal beta 1,3-galactosyltransferase polypeptide 6 (B3GALT6) NM_080605 8.00E-29
D6 Homo sapiens HLA-B associated transcript 2-like 1 (BAT2L1) NM_013318 4.00E-121
D7 Homo sapiens cDNA FLJ77629 complete cds, highly similar to Homo sapiens bone marrow
stromal cell antigen 2 (BST2)
AK291099 0.00E+00
D8 Homo sapiens basic transcription factor 3 (BTF3), transcript variant 1 NM_001037637 0.00E+00
D9 Homo sapiens complement component 1, s subcomponent (C1S), transcript variant 1 NM_201442 0.00E+00
D10 Homo sapiens CD74 molecule, major histocompatibility complex, class II invariant chain
(CD74), transcript variant 1
NM_001025159.1 8.00E-179
D11 Homo sapiens chloride intracellular channel 1 BC064527 2.00E-143
D12 Homo sapiens CXXC finger 1 (PHD domain) (CXXC1), transcript variant 1 NM_001101654 1.00E-180
D13 Homo sapiens early growth response 1 (EGR1) NM_001964.2 0.00E+00
D14 Homo sapiens Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously expressed
(FAU)
NM_001997 5.00E-99
D15 Homo sapiens F-box protein Fbx7 (FBX7) mRNA, complete cds AF129537 2.00E-105
D16 Homo sapiens Fc fragment of IgG, receptor, transporter, alpha BC008734 1.00E-79
D17 Homo sapiens forkhead box P1 (FOXP1), transcript variant 1 NM_032682 2.00E-130
D18 Homo sapiens guanine nucleotide binding protein (G protein), beta polypeptide 1 BC004186 1.00E-55
D19 Homo sapiens H19, imprinted maternally expressed transcript (non-protein coding) (H19),
non-coding RNA
NR_002196 2.00E-34
D20 Homo sapiens high density lipoprotein binding protein (HDLBP), transcript variant 2 NM_203346.2 0.00E+00
D21 Homo sapiens cDNA FLJ52975 complete cds, highly similar to Heterogeneous nuclear
ribonucleoproteins C
AK299923 0.00E+00
D22 Homo sapiens cDNA clone IMAGE:3898245 BC010864 1.00E-138
D23 Homo sapiens cDNA fis, A-KAT03057, highly similar to Homo sapiens mitochondrion, ATP
synthase 6
AK026530 0.00E+00
D24 Homo sapiens cDNA: FLJ21566 fis, clone COL06467 AK025219 0.00E+00
D25 Homo sapiens cDNA: FLJ22996 fis, clone KAT11938 AK026649 4.00E-132
D26 Homo sapiens coiled-coil-helix-coiled-coil-helix domain containing 1 (CHCHD1) NM_203298.1 0.00E+00
D27 Homo sapiens mRNA similar to guanine nucleotide binding protein-like 1 BC048213 6.00E-29
D28 Homo sapiens mRNA similar to ribosomal protein L30 BC012823 2.00E-131
D29 Homo sapiens ribosomal protein, large, P1 BC053844 5.00E-152
D30 Homo sapiens sarcoma antigen NY-SAR-71 mRNA, partial cds AY211920 1.00E-138
D31 Homo sapiens tumor necrosis factor, alpha-induced protein 1 (endothelial) BC006208 8.00E-116
D32 Homo sapiens zinc finger, FYVE domain containing 20 BC021246 1.00E-138
D33 Homo sapiens heat shock factor binding protein 1 (HSBP1) NM_001537 1.00E-121
D34 Homo sapiens HtrA serine peptidase 1 (HTRA1) on chromosome 10 NG_011554 0.00E+00
D35 Human mitochondrial specific single stranded DNA binding protein mRNA, complete cds M94556 1.00E-146
D36 Homo sapiens immunoglobulin kappa constant BC095490 0.00E+00
D37 Homo sapiens immunoglobulin lambda locus, mRNA (cDNA clone MGC:88803
IMAGE:4765294), complete cds
BC073786 3.00E-101
D38 Homo sapiens jun B proto-oncogene (JUNB) gene, complete cds AY751746 2.00E-20
D39 Homo sapiens L antigen family, member 3, mRNA (cDNA clone MGC:23038 IMAGE:4899044),
complete cds
BC015744 6.00E-29
D40 Homo sapiens laminin, beta 2 (laminin S) (LAMB2) NM_002292.3 0.00E+00
D41 Homo sapiens lectin, galactoside-binding, soluble, 1, mRNA (cDNA clone MGC:1818
IMAGE:2967299), complete cds
BC001693 5.00E-52
D42 Homo sapiens lectin, galactoside-binding, soluble, 3, mRNA (cDNA clone MGC:2058
IMAGE:3050135), complete cds
BC001120 0.00E+00
D43 Homo sapiens lectin, galactoside-binding, soluble, 3 (LGALS3), transcript variant 2, non-
coding RNA
NR_003225 0.00E+00
D44 Homo sapiens mRNA for LGALS3 protein variant protein AB209391 0.00E+00
D45 PREDICTED: Homo sapiens similar to ribosomal protein L13a (LOC100293761) XM_002344734 8.00E-51
D46 Homo sapiens mediator complex subunit 1 (MED1) NM_004774 1.00E-62
D47 Homo sapiens mediator complex subunit 14 (MED14) NM_004229 3.00E-49
D48 Homo sapiens myocyte enhancer factor 2C (MEF2C), transcript variant 2 NM_001131005 1.00E-99
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Page 7 of 14Table 2 Annotation of the 114 DEGs by the BLAST search (Continued)
D49 Homo sapiens murine retrovirus integration site 1 homolog (MRVI1), transcript variant 4 NM_001100167 0.00E+00
D50 Homo sapiens myosin light chain kinase (MYLK), transcript variant 3A NM_053027 2.00E-97
D51 Homo sapiens cDNA FLJ53659 complete cds, highly similar to Myosin light chain kinase,
smooth muscle
AK300610 0.00E+00
D52 Homo sapiens nuclear receptor co-repressor 2 (NCOR2), transcript variant 1 NM_006312.3 0.00E+00
D53 Homo sapiens nuclear enriched abundant transcript 1 (NEAT1) mRNA, complete sequence EF177379 1.00E-80
D54 Homo sapiens trophoblast MHC class II suppressor mRNA, complete sequence AF508303 1.00E-67
D55 Homo sapiens cDNA FLJ53682 complete cds, highly similar to RNA-binding protein 5 AK302766 2.00E-153
D56 Homo sapiens RNA binding motif protein 5 BC002957 2.00E-153
D57 Homo sapiens RNA binding motif protein 8A (RBM8A) NM_005105.2 1.00E-135
D58 Homo sapiens ribonuclease, RNase K (RNASEK) NM_001004333.3 6.00E-99
D59 Homo sapiens ribosomal protein L14 (RPL14), transcript variant 1 NM_001034996 0.00E+00
D60 Homo sapiens ribosomal protein L27a (RPL27A) NM_000990 4.00E-171
D61 Homo sapiens ribosomal protein L29 (RPL29) NM_000992.2 6.00E-154
D62 Homo sapiens ribosomal protein S16 (RPS16) NM_001020 7.00E-136
D63 Homo sapiens ribosomal protein S20 (RPS20), transcript variant 2 NM_001023 0.00E+00
D64 Homo sapiens ribosomal protein S21 (RPS21) NM_001024 8.00E-122
D65 Homo sapiens single-stranded DNA binding protein 1 BC000895 1.00E-146
D66 Homo sapiens transcription elongation factor A (SII)-like 2 (TCEAL2) NM_080390 0.00E+00
D67 Homo sapiens tubulointerstitial nephritis antigen-like 1 (TINAGL1) NM_022164 2.00E-153
D68 Homo sapiens transmembrane protein 185A (TMEM185A) NM_032508.1 0.00E+00
D69 Homo sapiens cDNA FLJ57738 complete cds, highly similar to Translationally-controlled
tumor protein
AK296587 2.00E-104
D70 Homo sapiens X-ray repair complementing defective repair in Chinese hamster cells 6
(XRCC6)
NM_001469.3 0.00E+00
D71 Homo sapiens cDNA FLJ53970 complete cds, highly similar to ATP-dependent DNA helicase
2 subunit 1
AK293439 0.00E+00
D72 Homo sapiens phosphodiesterase 7B (PDE7B) on chromosome 6 NG_011994 3.00E-41
The prefix U and D in the clone name represent the clone from the up- and down-regulated bands in the agarose gel. The expression of DEGs marked in bold
was further confirmed by quantitative real-time PCR.
Figure 3 Clustering of the log2 expression ratios of the cancer to normal samples measured by the quantitative real-time PCR for the
38 DEGs from the 16 patients and its representation as a heat map. Patients are ordered along the X-axis and genes along the Y-axis.
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Page 8 of 14groups 1 and 4 might be used as potential markers for
prognosis in patients with stage III serous ovarian cancer.
The group 1 consisted of: NM_003143.1 (SSBP1),
NM_022873.2 (IFI6), NM_001355.3 (DDT), NM_005532
(IFI27), NM_207429.2 (C11orf92), NM_020529
(NFKBIA), NM_032470 (TNXB), EF177379 (NEAT1)a n d
BC02359 (TFG) ;g r o u p4w a sc o m p o s e do f :
NM_002292.3 (LAMB2), AK025219, AK293439 (XRCC6),
NM_001131005 (MEF2C), AK302766 (RBM5),
NM_032682 (FOXP1), NG_001229 (NUDCP2), BC001120
(LGALS3), NM_032508.1 (TMEM185A), and NM_201442
(C1S) (Table 3). All genes except for NEAT1 in group 1
were identified from up-regulated clones while all genes
except for NUDCP2 in group 4 were identified from
down-regulated clones (Tables 2 and 3). These results
were in good agreement with the ACP findings.
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Figure 4 Kaplan-Meier estimates of overall survival stratified by up- and down-regulation for three genes including DDAH2, RNase K
and TCEAL2.
Table 3 Clustering of 38 DEGs according to the expression profiles of 16 patients with serous ovarian cancer; Up-
regulation corresponds to log2 ratio > threshold while down-regulation to log2 ratio < minus value of threshold
Threshold Group 1 Group 2 Group 3 Group 4
up-
regulated
down-
regulated
up-
regulated
down-
regulated
up-
regulated
down-
regulated
up-
regulated
down-
regulated
0.5 88.9% 6.9% 68.8% 15.6% 63.9% 22.2% 19.4% 68.8%
1.0 86.8% 5.6% 58.8% 12.5% 55.6% 18.1% 9.3% 60.3%
1.5 84.0% 4.2% 45.6% 7.5% 48.6% 13.2% 6.3% 46.3%
2.0 77.1% 3.5% 31.9% 6.9% 41.0% 11.8% 3.1% 33.1%
Accession no. (gene
symbol)
NM_003143.1 (SSBP1) AY871274 (RPL11) NM_001867 (COX7C)
BC013003 (ANP32B)
AK302766 (RBM5)
NM_032682 (FOXP1)
NM_022873.2 (IFI6) BC000523 (RPS24) BC013003 (ANP32B) NM_032682 (FOXP1)
NM_001355.3 (DDT) BC012823 NM_000978 (RPL23) NG_001229 (NUDCP2)
NM_005532(IFI27) NM_001101654(CXXC1) NM_013974.1 (DDAH2) AK025219
NM_207429.2 (C11orf92) NM_001034996(RPL14) XM_002345433 BC001120 (LGALS3)
NM_032508.1 (TMEM185A)
NM_020529(NFKBIA) NM_001037637(BTF3) BC107854 (ATP6V1F)
NM_032470(TNXB) NM_001020(RPS16) NM_001004333.3 (RNASEK) NM_002292.3 (LAMB2)
EF177379 (NEAT1) NR_003225(LGALS3) NM_080390(TCEAL2) AK293439 (XRCC6)
BC02359 (TFG) NM_013318(BAT2L1)
AK026649
NM_001100167(MRVI1) NM_001131005(MEF2C)
NM_201442 (C1S)
The percentage of up- and down-regulation was calculated for each group.
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Page 9 of 14Survival analysis
The Kaplan-Meier method was performed using the 38
DEGs that were up- and down-regulated. The up and
down regulated genes were considered according to the
log2 expression ratio > 0 and < 0, respectively. A signifi-
cant difference, in the overall survival (p values < 0.05)
between the up- and down-regulated group, was observed
for three DEGs including NM_013974.1 (dimethylarginine
dimethylaminohydrolase 2, DDAH2), NM_001004333.3
(ribonuclease K, RNase K) and NM_080390 (transcription
elongation factor A (SII)-like 2, TCEAL2) (Figure 4). The
overall survival decreased with up-regulation of these
genes. DDAH2 predominates in the vascular endothelium,
which is the site of endothelial nitric oxide synthase
(eNOS) expression [13,14]. TCEAL2 is a nuclear phospho-
protein that modulates transcription in a promoter con-
text-dependent manner and has been recognized as an
important nuclear target for intracellular signal transduc-
tion. The function of RNase K is unknown but might be
related to an enhanced degradation of the tumor suppres-
sor gene mRNAs, which leads to the development of can-
cer. The up-regulation of these three genes was observed
in more than 60% of the total number of patients.
The survival analysis also was performed for chemo-
resistance. Following debulking surgery, all patients
received platinum-based chemotherapy, considered the
standard of care for patients with advanced ovarian can-
cer. The patients that had either progression during che-
motherapy or relapse within six months of treatment
were considered chemo-resistant. Among 16 patients,
eight were classified as chemo-resistant and the others
were categorized as chemo-sensitive. The difference in
overall survival between these two groups was significant
(p value < 0.05, Figure 5). The shorter survival time of
patients with chemo-resistance is consistent with a prior
report [15]. To consider chemo-resistance and gene
expression simultaneously, in the prediction of overall
survival, the Cox multivariate analysis was carried out
with the expression information of 38 DEGs and chemo-
resistance information from 16 patients. Multivariate
analysis demonstrated a significant difference in overall
survival between the chemo-resistant and sensitive
groups for four DEGs including: NM_001004333.3
(RNase K), NM_032682 (forkhead box transcription fac-
tor family, FOXP1), NM_002292.3 (a family of extracellu-
lar matrix glycoproteins, LAMB2), and NM_001100167
(murine retrovirus integration site 1 homolog, MRVI1)
(p values < 0.05, Figure 6). The RNase K showed signifi-
cance in both univariate (gene expression) and multivari-
ate (gene expression and chemo-resistance) analysis
while DDAH2 and TCEAL2 showed significance only in
univariate analysis. This was mainly due to the similar
proportion of up- and down-regulation of DDAH2 and
TCEAL2 between the chemo-resistant and chemo-
sensitive groups. The overall survival of patients with
chemo-resistance was significantly decreased with up-
regulation of these four genes; while the chemo-sensitive
patients had down-regulation of these genes and a good
prognosis. FOXP1 has a diverse repertoire of functions
ranging from the regulation of B-cell development and
monocyte differentiation to the facilitation of cardiac
valve and lung development [16,17]. LAMB2 might be
involved in the cell adhesion or motility of prostate can-
cer cells [18]. The down-regulation of FOXP1 and
LAMB2 was observed in more than 60% of all patients
while MRVI was up-regulated among 63%.
Discussion
Ovarian cancer is the most common cause of death
among all gynecological malignancies. The five-year sur-
vival rates in patients with ovarian cancer are about
80-90% for stage Ia-Ic, 70-80% for stage IIa-IIc, 30-50%
for stages IIIa-IIIc and 13% for stage IV [19]. The high
rate of death is due to the fact that most of patients
(>60%) present with advanced stage disease (FIGO stages
III/IV). Despite an initial response rate of 65%-80% to
first-line chemotherapy, most ovarian carcinomas relapse.
Acquired resistance to further chemotherapy is generally
responsible for treatment failure. Several studies have
sought to identify gene expression signatures that corre-
late with clinical outcome to identify those genes that are
associated with survival and relapse and to use as predic-
tive biomarkers for response to chemotherapy [20-22].
There are many types of ovarian cancer. EOC accounts
for 85%-90%; half of such cases are serous EOC. As with
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Figure 5 Kaplan-Meier estimates of overall survival stratified
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Page 10 of 14many cancers thought to be of epithelial origin, it is
important to establish an appropriate control for evaluat-
ing differential gene expression between “normal” and
cancer. Expression profiling studies of ovarian cancer
have relied on a variety of sources of normal cells or
comparison with tumors, including whole ovary samples
(WO), ovarian surface epithelium (OSE), exposed to
short-term culture, and immortalized OSE cell lines
(IOSE) [23]. Direct comparison of the gene expression
profiles generated from OSE brushings, WO samples,
short-term cultures of normal OSE (NOSE), and telomer-
ase-immortalized OSE (TIOSE) cell lines revealed that
these “normal” samples formed robust, but very distinct
groups in hierarchical clustering [24]. These indicate that
the selection of normal control to compare epithelial
ovarian samples in microarray studies can strongly
influence the genes that are identified as differentially
expressed. In this study, the total RNA from WO (Strata-
gene, http://www.stratagene.com) was used as control.
WO samples have potential to obscure epithelial pattern
due to large amounts of stroma, but they offer the advan-
tages of avoidance of exposure to culture conditions and
identification of differential gene expression pattern
between tumor and normal tissue [25].
A total of 114 DEGs from patients with serous ovarian
cancer stage III were identified using the ACP-based
GeneFishing™ PCR system, which uses primers that
anneal specifically to the template and allows only genu-
ine products to be amplified. As the GeneFishing™ system
is based on PCR, it can overcome the difficulty in identi-
fying the genes responsible for a specialized function dur-
ing a certain biological stage; this is because the gene is
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Page 11 of 14expressed at low levels, whereas most mRNA transcripts
within a cell are abundantly expressed. Among the 114
DEGs, 42 were identified as up-regulated clones while 72
were down-regulated clones. These DEGs were involved
in a variety of biological processes including apoptosis,
signal transduction and the immune response. Apoptosis
inhibitory processes were associated with genes such as
NFKBIA, DDAH2 and IFI6 identified from up-regulated
clones; while the immune system associated genes such
as IGKC, CD74 and BST2 were found in down-regulated
clones. The differential expression of DEGs identified by
the Genefishing™ system showed good agreement with
the results of the quantitative real-time PCR.
Cluster analysis based on gene expression profiles iden-
tified two groups showing a contrast in the expression
pattern. That is, one group including: SSBP1, IFI6 DDT,
IFI27, C11orf92, NFKBIA, TNXB, NEAT1 and TFG,w a s
up-regulated in most patients with stage III serous ovar-
ian cancer (Figure 3 and Table 3). These genes might be
utilized as potential targets in patients with stage III ser-
ous ovarian cancer. IFI6 is involved in apoptosis inhibi-
tory activity while TGF is implicated in up regulation of
the I- Bk i n a s e / N F -  Bc a s c a d e .TNXB encodes TNX, a
protein of unknown function that is mainly expressed in
the peripheral nervous system and muscles. The promo-
tion of tumor invasion and metastasis has been reported
in mice deficient in TNX through the activation of
the matrix metalloproteinase 2 (MMP2)a n dMMP9
genes [26]. This indicates that the up-regulation of
TNXB, in patients with advanced stage of ovarian cancer,
might induce low expression of MMP2 and MMP9.T h e
decrease of MMP2 has been reported in liver metastases
in advanced colorectal cancers [27]. Another group con-
sists of LAMB2, XRCC6, MEF2C, RBM5, FOXP1,
NUDCP2, LGALS3, TMEM185A,a n dC1S,w h i c hw a s
down-regulated in most patients with stage III serous
ovarian cancer (Figure 4 and Table 3). The down-regula-
tion of LAMB2 and MEF2C might be involved with cell
adhesion or motility in invasive prostate cancer cells [18]
and apoptosis via BCL2 transformation [28], respectively.
FOXP1 is a potential therapeutic target in cancer and can
be considered either an oncogene and/or a tumor sup-
pressor gene [29]. That is, its over-expression confers a
poor prognosis in a number of types of lymphomas while
the loss of its expression in breast cancer is associated
with a poor outcome. The function of FOXP1 in serous
ovarian cancer remains unclear. LGALS3 encoding galec-
tin-3 has been implicated in advanced stage disease [30].
The distribution of galectin has been associated with
stage III-V with cellular changes such as dysplasia, cancer
cells’ nest formation, breakage of the basement mem-
brane, and infiltration of cells into non-native tissue.
However, 13 out of the total 16 patients with stage III
serous ovarian cancer had down-regulation of LGALS3.
This is consistent with the report by van den Brule et al.
[31] that showed that galectin-3 expression was
decreased in 67% of cases compared to the normal
epithelial cells. However, it conflicts with the observa-
tions of Lurisci et al. [32] that galectin-3 serum levels in
patients with ovarian cancer were significantly elevated.
The expression of LGALS3 might be affected by the stage
of ovarian cancer.
The overall survival estimated by the Kaplan-Meier
method was significantly different between the up- and
down-regulated patient cohort with regard to three
genes including DDAH2, RNase K and TCEAL2.T h e
up-regulation of these genes was associated with a
shorter overall survival (Figure 4). In rapidly growing
cells like tumor cells, the activity of RNases is decreased
[33], as dictated by the requirement of significant
amounts of RNA for protein synthesis. However, high
RNase activity has been reported in chronic myeloid
leukemia [34] and pancreatic carcinoma [35]. In this
study, 70% of the patients with stage III serous ovarian
cancer showed up-regulation of RNase K.T h ef u n c t i o n
of RNase K in advanced ovarian cancer remains to be
clarified. In addition, the overall survival of patients with
chemo-resistance was significantly decreased with up-
regulation of the genes including: RNase K, FOXP1,
LAMB2 and MRVI1 (Figure 6). This might implicate
these genes in chemoresistance.
Conclusion
One hundred and fourteen DEGs were identified from
16 patients with stage III serous ovarian carcinoma
using the ACP-based RT-PCR technique. Fifteen per-
cent of the total DEGs were associated with apoptosis,
the immune response, cell adhesion, and signal path-
ways. The genes related to apoptosis inhibitory pro-
cesses tended to be up-regulated while the genes
associated with the immune response tended to be
down-regulated. The up- and down-regulated genes
were identified in most of the patients and might be
used as predictive markers in stage III serous ovarian
cancer.
Additional material
Additional file 1: The log2 expression ratios, of cancer to normal
samples measured by the quantitative real-time PCR, for the 38
DEGs from 16 patients.
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